To hear about similar clinical trials, please enter your email below
Trial Title:
Prevelance Of Cutaneous Disorders Among Patients With Heamatologic Malignancies
NCT ID:
NCT06108622
Condition:
Dermatologic Disorders With Heamatologic Malignancies Patients
Conditions: Official terms:
Neoplasms
Skin Diseases
Study type:
Observational
Overall status:
Not yet recruiting
Study design:
Time perspective:
Cross-Sectional
Intervention:
Intervention type:
Diagnostic Test
Intervention name:
cbc ,u\s renalor hepatic function test if needed
Description:
just blood sample if the case needed
Summary:
Hematologic malignancies are a diverse group of neoplasms that can have a wide range of
clinical and behavioral characteristics. Infections are also a common complication of
hematologic malignancies, and can manifest as cutaneous eruptions. Hair loss is a common
symptom of hematological malignancies. Changes in the nails can also occur in patients
with hematological malignancies. Chemotherapy and radiotherapy are two common treatments
for hematological malignancies. patients may experience a wide range of side effects,
including hair loss, changes in the nails, and mucositis (
Detailed description:
hematologic malignancies are a diverse group of neoplasms that can have a wide range of
clinical and behavioral characteristics. The skin is often involved in these diseases,
either through direct infiltration by malignant cells or through non-specific changes
such as pallor and ecchymosis. Cutaneous involvement can have a significant impact on the
quality of life of patients with hematologic malignancies and can also compromise
prognosis in certain cases Cutaneous manifestations of hematologic malignancies have
become increasingly common. This is partly due to the availability of new drugs that have
improved the prognosis of these patients, but also come with an increased risk of skin
toxicity. Furthermore, the effectiveness of these therapies has led to increased
survival, which in turn has allowed for the emergence of skin eruptions that were not as
frequently seen in the past due to the shorter duration of the natural history of cancer
Some of the most common manifestations include petechiae, purpura, erythroderma, palpable
purpura, Sweet's syndrome and paraneoplastic pemphigus Infections are also a common
complication of hematologic malignancies, and can manifest as cutaneous eruptions. For
example, patients with leukemia and other blood cancers are at increased risk for
developing fungal infections such as candidiasis and aspergillosis, which can present as
red, scaly, and itchy skin. Other infections, such as cellulitis, can also occur as a
complication of hematologic malignancies and can present with red, swollen, and warm skin
Hair loss is a common symptom of hematological malignancies. The cancer cells can
interfere with the growth and maintenance of hair follicles, leading to hair loss. Hair
loss can be patchy or diffuse, and can occur on the2 scalp, face, or body. In some cases,
hair loss can be 2ry to treatment or sign of the progression of the disease. Changes in
the nails can also occur in patients with hematological malignancies. The nails may
become discolored, brittle, or develop ridges or grooves. In some cases, the nails may
also separate from the nail bed. These changes are typically caused by the cancer cells
affecting the blood flow to the nails or by the cancer treatment Mucous membranes can
also be affected by hematological malignancies. The cancer cells can cause inflammation,
soreness, and dryness in the mucous membranes, leading to a condition called mucositis.
Mucositis can make it difficult to eat or speak, and can increase the risk of infection.
Chemotherapy and radiotherapy are two common treatments for hematological malignancies.
These treatments are designed to kill cancer cells or shrink tumors, but they can also
affect healthy cells in the body. As a result, patients may experience a wide range of
side effects, including hair loss, changes in the nails, and mucositis
. Other common side effects of chemotherapy include nausea, vomiting, fatigue, and an
increased risk of infection. Radiation therapy can cause skin reactions, fatigue, and a
risk of secondary cancer. Side effects can vary widely depending on the type of cancer
and the specific drugs and radiation regimens used. Each patient may experience different
side effects, and the intensity and duration of the side effects also vary
Criteria for eligibility:
Study pop:
- A cross - sectional study will include patients who attending and/or admitted to
Clinical Oncology and Nuclear Medicine Department Sohag university Hospital.
- The study protocol will be approved by the Local Ethics and scientific Committee in
Sohag faculty of medicine .
- Written informed consents will be obtained from all patients
Sampling method:
Probability Sample
Criteria:
Inclusion Criteria:
- Age: all age groups.
- Sex: both sex will be included.
- Patients with confirmed diagnosis of haematological malignancies ethier
clinically or laboratory.
Exclusion Criteria:
- Pregnancy., • Patients with medical comorbidities (liver ,renal ,thyroid
abnormalities ,other malignancies)
Gender:
All
Minimum age:
N/A
Maximum age:
N/A
Locations:
Facility:
Name:
Sohag university Hospital
Address:
City:
Sohag
Zip:
Sohag
Country:
Egypt
Contact:
Last name:
Magdy M Amin, professor
Start date:
November 2023
Completion date:
November 2024
Lead sponsor:
Agency:
Sohag University
Agency class:
Other
Source:
Sohag University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06108622